| Schedule of Disaggregation of Revenue |
The Company’s revenues disaggregated by product category and geography for the three and nine months ended September 30, 2026 and 2025 were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
September 30, |
|
|
|
United States |
|
|
International |
|
|
Total |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Glaucoma |
|
$ |
118,635 |
|
|
$ |
80,806 |
|
|
$ |
33,356 |
|
|
$ |
29,443 |
|
|
$ |
151,991 |
|
|
$ |
110,249 |
|
Corneal Health |
|
|
56,212 |
|
|
|
20,645 |
|
|
|
2,827 |
|
|
|
2,643 |
|
|
|
59,039 |
|
|
|
23,288 |
|
Total |
|
$ |
174,847 |
|
|
$ |
101,451 |
|
|
$ |
36,183 |
|
|
$ |
32,086 |
|
|
$ |
211,030 |
|
|
$ |
133,537 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
September 30, |
|
|
|
United States |
|
|
International |
|
|
Total |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Glaucoma |
|
$ |
330,637 |
|
|
$ |
212,216 |
|
|
$ |
105,794 |
|
|
$ |
89,703 |
|
|
$ |
436,431 |
|
|
$ |
301,919 |
|
Corneal Health |
|
|
103,293 |
|
|
|
54,824 |
|
|
|
7,487 |
|
|
|
7,578 |
|
|
|
110,780 |
|
|
|
62,402 |
|
Total |
|
$ |
433,930 |
|
|
$ |
267,040 |
|
|
$ |
113,281 |
|
|
$ |
97,281 |
|
|
$ |
547,211 |
|
|
$ |
364,321 |
|
|
| Schedule of Accrued Sale Rebate Liability Activity |
|
|
|
|
|
|
|
September 30, |
|
|
|
2026 |
|
Reserve balance, December 31, 2025 |
|
$ |
10,192 |
|
Current period provision |
|
|
14,246 |
|
Payments and credits |
|
|
(9,767 |
) |
Reserve balance, September 30, 2026 |
|
$ |
14,671 |
|
|